GLP-1 Agonists in Surgery: Perioperative Physiology & Protocol

The GLP-1 Surgical Problem: Why Perioperative Protocol Matters

The American College of Surgeons' recent guidance on GLP-1 agonist management in the operating room reflects a critical gap: these medications fundamentally alter glucose homeostasis and gastrointestinal motility in ways that directly impact surgical outcomes. Semaglutide (Ozempic, Wegovy), tirzepatide (Zepbound), and their analogs work by activating glucagon-like peptide-1 receptors on pancreatic beta cells, enhancing insulin secretion in a glucose-dependent manner. But they also slow gastric emptying—which carries real perioperative risk.

Mechanism: Why GLP-1s Create Surgical Complexity

GLP-1 receptor agonists suppress ghrelin, enhance satiety signaling in the hypothalamus, and critically, delay gastric emptying by 20-40% through direct effects on antral smooth muscle. This is therapeutic for weight loss. It becomes a liability during general anesthesia.

Delayed gastric emptying increases aspiration risk during intubation and extubation. The medication also increases insulin sensitivity—meaning standard intraoperative glucose management protocols may undershoot, risking hypoglycemia. Conversely, the acute stress response to surgery can overwhelm the GLP-1 mechanism, causing hyperglycemia rebound.

Additionally, GLP-1 agonists can cause nausea, vomiting, and dehydration. Perioperative volume depletion combined with enhanced insulin sensitivity creates hemodynamic and metabolic instability.

Preoperative Assessment & Timing Protocol

Any patient on a GLP-1 agonist should disclose this to the surgical team at preoperative evaluation. The timing of the last dose matters:

• Short-acting agents (daily semaglutide injections): Hold the morning of surgery. Resume 24 hours post-op if tolerating oral intake.
• Long-acting agents (weekly semaglutide, tirzepatide): Discontinue 3-7 days before elective surgery. Coordinate timing with the surgeon; for urgent procedures, proceed with caution and enhanced glucose monitoring.

Intraoperative Glucose Management

Standard point-of-care glucose testing is insufficient. Patients on GLP-1s benefit from continuous glucose monitoring (CGM) data pre-op and intraoperative blood glucose checks every 30-60 minutes, not the typical 4-hour intervals. Target intraoperative glucose: 140-180 mg/dL (not the traditional 100-150 mg/dL)—the slightly elevated range accounts for the medication's enhanced insulin effect and prevents overcorrection-induced hypoglycemia.

Use insulin judiciously. Many anesthesiologists reduce insulin infusion rates by 25-40% in GLP-1 users because baseline insulin sensitivity is elevated.

Postoperative Considerations

Nausea and vomiting increase post-op. Standard antiemetic regimens (ondansetron, dexamethasone) should be anticipated. Restart GLP-1 agents only after the patient is reliably tolerating oral intake—typically day 1 or 2 post-op.

Monitor for delayed gastric recovery. If the patient cannot tolerate solid food by post-op day 2-3, consider whether the GLP-1 resumption is premature.

Blood Testing Before and After Surgery

Preoperative labs should include:

• Fasting glucose and HbA1c: Establish baseline glycemic control.
• Basic metabolic panel (BMP): Assess kidney function (relevant because GLP-1s may be contraindicated in eGFR <30) and electrolytes.
• Insulin and C-peptide (fasting): Determine degree of insulin sensitization from the GLP-1 agent.
• TSH and free T4: GLP-1 agonists have been associated with thyroid nodules; baseline imaging or labs help rule out malignancy.

Postoperative labs (day 1-2):

• BMP and glucose: Confirm metabolic stability off the GLP-1 agonist.
• Lipase: Screen for pancreatitis, a rare but serious GLP-1 complication.

Synergistic Supplements & Glucose Support During Perioperative Window

If the patient is resuming GLP-1 therapy post-op, certain synergistic nutrients can stabilize glucose and reduce nausea:

• Berberine (500 mg TID): Activates AMPK, enhances glucose uptake; coordinates with GLP-1's mechanism. Resume after day 3 post-op.
• Magnesium glycinate (400-500 mg daily): Improves insulin sensitivity, reduces nausea. Safe to use perioperatively if kidney function is normal.
• Zinc (15-30 mg elemental): Supports immune recovery and wound healing post-op; coordinated with GLP-1 therapy improves insulin signaling.

Bottom Line

GLP-1 agonists are no longer a niche medication—surgeons will encounter them routinely. The key is preoperative disclosure, coordinated cessation, enhanced intraoperative glucose monitoring, and cautious resumption post-op. These medications work through precise endocrine mechanisms; perioperative protocol must respect that biology. American College of Surgeons guidelines now explicitly recommend a multidisciplinary approach involving anesthesia, surgery, and endocrinology for optimal outcomes.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.